— Know what they know.
Not Investment Advice

RXRX NASDAQ

Recursion Pharmaceuticals, Inc.
1W: +2.3% 1M: -16.6% 3M: -9.1% YTD: -25.9% 1Y: -31.6% 3Y: -39.4% 5Y: -85.3%
$3.01
-0.10 (-3.22%)
 
Weekly Expected Move ±7.1%
$3 $3 $3 $3 $3
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 31 · $1.3B mcap · 348M float · 3.94% daily turnover · Short 57% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
45.9 / 100
NoneWeakNarrowWide
Primary source: Switching Costs  ·  ROIC: -99.3%  ·  5Y Avg: 48.8%
Cost Advantage
34
Intangibles
26
Switching Cost
74
Network Effect
72
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. RXRX shows a Weak competitive edge (45.9/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Switching Costs. Negative ROIC of -99.3% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$6
Low
$6
Avg Target
$6
High
Based on 1 analyst since May 6, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 4Hold: 6Sell: 0Strong Sell: 0
Rating Summary
ConsensusHold
Avg Target$5.50
Analysts1
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-14 Morgan Stanley $11 $6 -6 +78.6% $3.08
2025-12-17 Morgan Stanley Initiated $11 +161.9% $4.20
2025-12-17 UBS Initiated $11 +161.9% $4.20
2025-02-28 Leerink Partners Initiated $6 -20.1% $7.51
2024-09-04 Needham Gil Blum Initiated $11 +80.3% $6.10
2024-09-03 KeyBanc Scott Schoenhaus $16 $12 -4 +97.7% $6.07
2024-09-03 Jefferies Dennis Ding Initiated $6 -0.3% $6.02
2024-06-26 KeyBanc Scott Schoenhaus Initiated $16 +82.6% $8.76

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
May 22, 2026
DCF
1
ROE
1
ROA
1
D/E
3
P/E
1
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. RXRX receives an overall rating of C. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-05-04 C- C
2026-04-01 C C-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

28 Grade D
Profitability
0
Balance Sheet
0
Earnings Quality
25
Growth
61
Value
48
Momentum
58
Safety
15
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. RXRX scores highest in Growth (61/100) and lowest in Profitability (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
0.18
Distress Zone
Piotroski F-Score
5/9
Beneish M-Score
-3.95
Unlikely Manipulator
Ohlson O-Score
-6.25
Bankruptcy prob: 0.2%
Low Risk
Credit Rating
BB-
Score: 37.1/100
Trend: Deteriorating
Earnings Quality
OCF/NI: 0.57x
Accruals: -16.3%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. RXRX scores 0.18, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. RXRX scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. RXRX's score of -3.95 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. RXRX's implied 0.2% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. RXRX receives an estimated rating of BB- (score: 37.1/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-2.85x
PEG
-0.08x
P/S
20.31x
P/B
1.55x
P/FCF
-4.99x
P/OCF
EV/EBITDA
-1.97x
EV/Revenue
14.48x
EV/EBIT
-1.68x
EV/FCF
-2.95x
Earnings Yield
-34.45%
FCF Yield
-20.05%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. RXRX currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.992
NI / EBT
×
Interest Burden
0.990
EBT / EBIT
×
EBIT Margin
-8.603
EBIT / Rev
×
Asset Turnover
0.045
Rev / Assets
×
Equity Multiplier
1.350
Assets / Equity
=
ROE
-51.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. RXRX's ROE of -51.7% is driven by Asset Turnover (0.045), indicating efficient use of assets to generate revenue. A tax burden ratio of 0.99 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1282 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$3.01
Median 1Y
$1.27
5th Pctile
$0.28
95th Pctile
$5.67
Ann. Volatility
90.3%
Analyst Target
$5.50
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Christopher Gibson, current
Chief Executive Officer and President and current Chair of the Board
$680,000 $3,808,302 $9,607,508
Najat Khan, current
Chief Executive Officer and President
$600,000 $1,944,547 $5,349,065
Ben Taylor, Financial
ancial Officer
$538,680 $253,881 $1,328,483

CEO Pay Ratio

10881:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $9,607,508
Avg Employee Cost (SGA/emp): $883
Employees: 200,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
200,000
+24900.0% YoY
Revenue / Employee
$373
Rev: $74,681,000
Profit / Employee
$-3,224
NI: $-644,759,000
SGA / Employee
$883
Avg labor cost proxy
R&D / Employee
$2,126
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE 21.0% 44.0% -28.7% -39.0% -1.4% -1.5% -46.6% -48.4% -50.5% -56.9% -69.1% -74.6% -79.0% -79.6% -61.9% -76.7% -86.6% -95.5% -59.5% -51.7% -51.70%
ROA -14.5% -30.4% -25.5% -34.7% -51.5% -54.3% -36.5% -37.9% -39.6% -44.6% -48.4% -52.3% -55.3% -55.7% -44.1% -54.7% -61.7% -68.1% -44.1% -38.3% -38.31%
ROIC 7.1% 15.2% -3.2% -4.3% -4.9% -5.2% 14.8% 15.7% 16.6% 18.8% -2.3% -2.4% -2.5% -2.5% -68.9% -82.6% -93.5% -1.0% -1.1% -99.3% -99.32%
ROCE -14.8% -32.0% -27.2% -37.1% -41.5% -43.8% -39.8% -41.4% -43.2% -48.7% -59.2% -64.0% -67.8% -68.1% -36.7% -45.5% -51.3% -56.6% -48.5% -43.0% -42.99%
Gross Margin 1.0% 1.0% 1.0% -47.2% -85.9% -18.0% 20.7% -2.6% 14.8% -7.7% 7.0% 17.2% 36.1% 53.7% -1.8% -48.0% -5.5% -4.7% 24.4% -93.0% -92.99%
Operating Margin -16.4% -18.6% -26.0% -10.6% -8.6% -4.8% -4.5% -5.8% -7.4% -9.9% -9.3% -7.1% -7.0% -3.8% -40.7% -13.0% -9.2% -33.3% -3.0% -19.9% -19.86%
Net Margin -17.4% -19.0% -26.0% -10.6% -8.6% -4.6% -4.2% -5.4% -7.0% -9.2% -8.8% -6.8% -6.8% -3.7% -39.7% -13.7% -9.0% -31.4% -3.0% -18.2% -18.16%
EBITDA Margin -15.4% -17.9% -24.9% -10.0% -8.2% -4.4% -4.0% -5.1% -6.5% -8.5% -8.4% -6.3% -6.2% -3.4% -36.7% -12.4% -7.7% -27.3% -2.5% -16.8% -16.82%
FCF Margin -15.9% -16.5% -19.8% -5.9% -6.3% -4.7% -3.0% -5.9% -5.3% -5.9% -6.8% -7.3% -7.1% -5.2% -6.4% -6.7% -6.1% -10.3% -5.1% -4.9% -4.92%
OCF Margin -13.5% -13.3% -17.0% -3.9% -4.4% -3.5% -2.1% -5.0% -4.8% -5.5% -6.6% -7.0% -6.8% -4.9% -6.1% -6.5% -5.9% -10.1% -5.0% -4.8% -4.84%
ROE 3Y Avg snapshot only -60.48%
ROE 5Y Avg snapshot only -54.33%
ROA 3Y Avg snapshot only -43.94%
ROIC Economic snapshot only -38.29%
Cash ROA snapshot only -21.77%
Cash ROIC snapshot only -68.94%
CROIC snapshot only -69.99%
NOPAT Margin snapshot only -6.98%
Pretax Margin snapshot only -8.51%
R&D / Revenue snapshot only 6.35%
SGA / Revenue snapshot only 2.36%
SBC / Revenue snapshot only 1.13%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -141.65 -42.70 -18.63 -5.77 -5.99 -7.47 -5.98 -5.14 -5.79 -5.60 -7.01 -6.65 -4.84 -4.93 -4.90 -3.71 -3.25 -3.05 -3.34 -2.90 -2.846
P/S Ratio 2459.02 775.59 386.84 95.49 78.09 64.74 36.08 27.48 30.16 34.94 52.40 52.02 37.36 28.83 38.84 35.66 32.77 50.11 28.89 24.51 20.306
P/B Ratio -29.80 -18.80 5.34 2.25 2.58 3.40 2.95 2.63 3.10 3.38 4.96 5.08 3.92 4.02 2.20 2.06 2.04 2.11 1.90 1.44 1.555
P/FCF -154.21 -46.94 -19.57 -16.25 -12.36 -13.79 -11.84 -4.69 -5.66 -5.93 -7.65 -7.12 -5.26 -5.55 -6.04 -5.31 -5.36 -4.87 -5.69 -4.99 -4.987
P/OCF
EV/EBITDA -153.00 -43.57 -16.45 -3.61 -4.02 -5.68 -4.10 -3.30 -4.11 -4.19 -6.36 -6.08 -4.24 -4.34 -4.18 -3.13 -2.79 -2.66 -2.66 -1.97 -1.974
EV/Revenue 2360.43 726.30 319.49 56.02 49.95 47.02 23.50 16.75 20.16 24.31 44.63 44.49 30.35 23.55 30.53 27.53 25.23 38.95 19.97 14.48 14.477
EV/EBIT -144.28 -41.22 -15.66 -3.43 -3.84 -5.43 -3.90 -3.13 -3.87 -3.90 -5.90 -5.61 -3.88 -3.98 -3.86 -2.87 -2.51 -2.37 -2.31 -1.68 -1.683
EV/FCF -148.03 -43.95 -16.16 -9.54 -7.91 -10.02 -7.71 -2.86 -3.78 -4.12 -6.52 -6.09 -4.27 -4.53 -4.75 -4.10 -4.12 -3.78 -3.94 -2.95 -2.945
Earnings Yield -0.7% -2.3% -5.4% -17.3% -16.7% -13.4% -16.7% -19.5% -17.3% -17.8% -14.3% -15.0% -20.6% -20.3% -20.4% -27.0% -30.7% -32.8% -29.9% -34.4% -34.45%
FCF Yield -0.6% -2.1% -5.1% -6.2% -8.1% -7.2% -8.4% -21.3% -17.7% -16.9% -13.1% -14.1% -19.0% -18.0% -16.6% -18.8% -18.7% -20.5% -17.6% -20.1% -20.05%
Price/Tangible Book snapshot only 2.467
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 11.53 11.53 11.46 11.46 11.46 11.46 5.68 5.68 5.68 5.68 4.70 4.70 4.70 4.70 3.81 3.81 3.81 3.81 5.50 5.50 5.503
Quick Ratio 11.53 11.53 11.46 11.46 11.46 11.46 5.68 5.68 5.68 5.68 4.70 4.70 4.70 4.70 3.81 3.81 3.81 3.81 5.50 5.50 5.503
Debt/Equity -0.08 -0.08 0.02 0.02 0.02 0.02 0.10 0.10 0.10 0.10 0.11 0.11 0.11 0.11 0.10 0.10 0.10 0.10 0.07 0.07 0.069
Net Debt/Equity -0.93 -0.93 -0.93 -0.93 -1.03 -1.03 -1.03 -1.03 -0.74 -0.74 -0.74 -0.74 -0.47 -0.47 -0.47 -0.47 -0.59 -0.59 -0.588
Debt/Assets 0.05 0.05 0.02 0.02 0.02 0.02 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.07 0.07 0.07 0.07 0.05 0.05 0.053
Debt/EBITDA -0.41 -0.19 -0.08 -0.06 -0.05 -0.05 -0.22 -0.22 -0.21 -0.19 -0.16 -0.15 -0.15 -0.14 -0.25 -0.21 -0.19 -0.17 -0.14 -0.16 -0.160
Net Debt/EBITDA 6.39 2.96 3.47 2.54 2.26 2.14 2.19 2.11 2.04 1.83 1.11 1.03 0.98 0.97 1.14 0.93 0.83 0.76 1.19 1.37 1.368
Interest Coverage -16.35 -32.38 -56.21 -76.37 -934.68 -5741.74 -4433.74 -4216.36 -3660.85 -3523.86 -3458.68 -3699.56 -816.83 -384.65 -294.67 -369.34 -394.98 -372.31 -490.41 -342.92 -342.919
Equity Multiplier -1.45 -1.45 1.12 1.12 1.12 1.12 1.44 1.44 1.44 1.44 1.41 1.41 1.41 1.41 1.40 1.40 1.40 1.40 1.30 1.30 1.304
Cash Ratio snapshot only 5.032
Debt Service Coverage snapshot only -292.382
Cash to Debt snapshot only 9.534
FCF to Debt snapshot only -4.179
Defensive Interval snapshot only 498.4 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.01 0.02 0.01 0.02 0.04 0.06 0.06 0.07 0.08 0.07 0.06 0.07 0.07 0.10 0.06 0.06 0.06 0.04 0.05 0.05 0.045
Inventory Turnover
Receivables Turnover 16.03 32.05 220.59 376.44 188.97 300.05 28.48 33.38 35.79 33.68 15.01 15.47 16.63 22.10 2.24 2.29 2.47 1.67 2.02 1.80 1.796
Payables Turnover 0.00 0.00 0.00 2.77 11.32 19.23 13.04 14.29 12.99 11.76 9.97 9.67 9.63 9.91 3.54 4.37 5.23 6.60 4.96 4.49 4.486
DSO 23 11 2 1 2 1 13 11 10 11 24 24 22 17 163 160 148 219 181 203 203.2 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 132 32 19 28 26 28 31 37 38 38 37 103 83 70 55 74 81 81.4 days
Cash Conversion Cycle -131 -30 -18 -15 -15 -18 -20 -12 -14 -16 -20 60 76 78 164 107 122 121.9 days
Fixed Asset Turnover snapshot only 0.391
Cash Velocity snapshot only 0.089
Capital Intensity snapshot only 22.238
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 6.2% 4.7% 4.3% 2.6% 1.8% 64.6% 10.6% -2.8% -2.5% 37.7% 33.3% 32.1% 32.5% -32.6% 27.5% 11.0% 10.96%
Net Income -4.4% -1.7% -53.7% -17.5% -11.2% -18.5% -37.0% -42.3% -44.2% -29.1% -41.3% -62.3% -73.1% -89.5% -39.1% 2.6% 2.58%
EPS -4.3% -1.6% -40.2% -4.7% 5.0% 4.1% -9.1% -15.5% -19.9% 2.1% 2.0% 4.9% -0.4% -19.8% 11.3% 25.9% 25.87%
FCF -1.8% -61.9% 18.5% -2.6% -1.3% -1.1% -1.5% -21.3% -30.0% -21.4% -25.3% -21.3% -14.1% -33.5% -0.5% 18.8% 18.75%
EBITDA -4.8% -1.8% -56.3% -18.7% -9.6% -15.5% -35.1% -40.1% -42.5% -28.8% -38.7% -58.6% -67.5% -81.5% -31.3% 7.3% 7.34%
Op. Income -4.7% -1.9% -61.4% -24.6% -17.8% -25.0% -42.5% -45.0% -43.7% -26.3% -36.8% -52.5% -64.3% -83.6% -35.3% -2.0% -1.96%
OCF Growth snapshot only 17.46%
Asset Growth snapshot only 1.76%
Equity Growth snapshot only 9.29%
Debt Growth snapshot only -28.14%
Shares Change snapshot only 31.42%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 1.7% 1.3% 98.3% 67.1% 53.1% 15.2% 23.4% 12.5% 12.53%
Revenue 5Y
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y 44.2% 64.5% 20.9% -8.4%
Gross Profit 5Y
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 29.8% 29.8% 33.4% 33.4% 33.4% 33.4% 28.1% 28.1% 28.10%
Assets 5Y
Equity 3Y 24.0% 24.0% 24.0% 24.0% 32.5% 32.5% 32.53%
Book Value 3Y -1.3% -6.9% -7.7% -9.6% -6.4% -5.5% -5.54%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.96 1.00 0.84 0.72 0.88 1.00 0.89 0.81 0.83 0.30 0.95 0.86 0.862
Earnings Stability 0.84 0.91 1.00 0.93 0.92 0.95 0.99 0.89 0.92 0.88 0.97 0.90 0.901
Margin Stability 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 0.00 0.00 1.00 1.00 0.50 0.50 0.00 1.00 1.00 1.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.500
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.96 0.93 0.85 0.83 0.82 0.88 0.83 0.50 0.50 0.50 0.84 0.99 0.990
Earnings Smoothness
ROE Trend -0.32 -0.31 -0.33 -0.29 0.15 0.08 0.04 0.02 0.01 0.16 0.165
Gross Margin Trend -0.35 -0.27 -0.36 -0.04 0.25 0.47 0.32 0.09 -0.13 -1.15 -0.45 -0.42 -0.420
FCF Margin Trend 5.80 4.72 4.56 -1.44 -1.28 0.10 -1.49 -0.13 0.10 -4.75 1.57 2.10 2.096
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.78 0.73 0.82 0.24 0.34 0.40 0.35 0.94 0.92 0.88 0.88 0.89 0.88 0.84 0.77 0.68 0.59 0.62 0.58 0.57 0.573
FCF/OCF 1.18 1.24 1.16 1.49 1.45 1.34 1.45 1.16 1.11 1.07 1.04 1.04 1.04 1.06 1.05 1.03 1.03 1.02 1.02 1.02 1.015
FCF/Net Income snapshot only 0.582
CapEx/Revenue 2.5% 3.2% 2.7% 1.9% 1.9% 1.2% 94.1% 82.5% 51.8% 38.6% 28.6% 30.7% 29.0% 27.6% 29.1% 20.5% 17.4% 15.8% 8.7% 7.4% 7.38%
CapEx/Depreciation snapshot only 0.058
Accruals Ratio -0.03 -0.08 -0.05 -0.26 -0.34 -0.32 -0.24 -0.02 -0.03 -0.05 -0.06 -0.06 -0.06 -0.09 -0.10 -0.18 -0.25 -0.26 -0.19 -0.16 -0.163
Sloan Accruals snapshot only 0.037
Cash Flow Adequacy snapshot only -65.567
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield 0.0% 0.0% 0.0% -0.2% -0.3% -0.3% -10.4% -11.5% -9.6% -11.8% -5.6% -5.9% -22.0% -19.7% -13.2% -15.5% -8.1% -18.8% -24.7% -30.2% -30.24%
Total Shareholder Return 0.0% 0.0% 0.0% -0.2% -0.3% -0.3% -10.4% -11.5% -9.6% -11.8% -5.6% -5.9% -22.0% -19.7% -13.2% -15.5% -8.1% -18.8% -24.7% -30.2% -30.24%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.99 0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 0.99 0.992
Interest Burden (EBT/EBIT) 1.06 1.03 1.02 1.01 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.99 0.990
EBIT Margin -16.36 -17.62 -20.41 -16.33 -13.02 -8.66 -6.03 -5.35 -5.21 -6.23 -7.57 -7.93 -7.81 -5.91 -7.92 -9.59 -10.04 -16.40 -8.64 -8.60 -8.603
Asset Turnover 0.01 0.02 0.01 0.02 0.04 0.06 0.06 0.07 0.08 0.07 0.06 0.07 0.07 0.10 0.06 0.06 0.06 0.04 0.05 0.05 0.045
Equity Multiplier -1.45 -1.45 1.12 1.12 2.70 2.70 1.27 1.27 1.27 1.27 1.43 1.43 1.43 1.43 1.40 1.40 1.40 1.40 1.35 1.35 1.350
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-0.26 $-0.54 $-0.92 $-1.24 $-1.36 $-1.42 $-1.29 $-1.30 $-1.29 $-1.37 $-1.41 $-1.50 $-1.55 $-1.34 $-1.38 $-1.43 $-1.55 $-1.60 $-1.22 $-1.06 $-1.06
Book Value/Share $-1.22 $-1.22 $3.21 $3.18 $3.15 $3.13 $2.62 $2.54 $2.41 $2.27 $1.99 $1.96 $1.91 $1.64 $3.08 $2.57 $2.48 $2.32 $2.15 $2.14 $1.94
Tangible Book/Share $-1.24 $-1.24 $3.19 $3.17 $3.14 $3.12 $2.61 $2.52 $2.40 $2.26 $1.61 $1.59 $1.55 $1.33 $1.64 $1.37 $1.32 $1.23 $1.25 $1.24 $1.24
Revenue/Share $0.01 $0.03 $0.04 $0.07 $0.10 $0.16 $0.21 $0.24 $0.25 $0.22 $0.19 $0.19 $0.20 $0.23 $0.17 $0.15 $0.15 $0.10 $0.14 $0.13 $0.13
FCF/Share $-0.24 $-0.49 $-0.88 $-0.44 $-0.66 $-0.77 $-0.65 $-1.42 $-1.32 $-1.29 $-1.29 $-1.40 $-1.43 $-1.19 $-1.12 $-1.00 $-0.94 $-1.00 $-0.72 $-0.62 $-0.62
OCF/Share $-0.20 $-0.40 $-0.75 $-0.30 $-0.46 $-0.58 $-0.45 $-1.22 $-1.19 $-1.21 $-1.23 $-1.34 $-1.37 $-1.12 $-1.07 $-0.97 $-0.92 $-0.99 $-0.71 $-0.61 $-0.61
Cash/Share $1.56 $1.56 $3.05 $3.03 $3.00 $2.98 $2.96 $2.87 $2.73 $2.57 $1.68 $1.66 $1.62 $1.39 $1.77 $1.48 $1.42 $1.33 $1.41 $1.40 $1.24
EBITDA/Share $-0.23 $-0.49 $-0.86 $-1.17 $-1.30 $-1.36 $-1.23 $-1.23 $-1.21 $-1.27 $-1.32 $-1.40 $-1.44 $-1.24 $-1.27 $-1.30 $-1.40 $-1.42 $-1.06 $-0.92 $-0.92
Debt/Share $0.09 $0.09 $0.07 $0.07 $0.07 $0.07 $0.27 $0.27 $0.25 $0.24 $0.22 $0.21 $0.21 $0.18 $0.32 $0.27 $0.26 $0.24 $0.15 $0.15 $0.15
Net Debt/Share $-1.46 $-1.46 $-2.98 $-2.96 $-2.93 $-2.91 $-2.69 $-2.60 $-2.48 $-2.33 $-1.46 $-1.44 $-1.41 $-1.21 $-1.45 $-1.21 $-1.16 $-1.09 $-1.26 $-1.26 $-1.26
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 0.178
Altman Z-Prime snapshot only 0.740
Piotroski F-Score 2 2 2 2 3 3 3 4 4 4 2 3 3 3 3 2 2 2 5 5 5
Beneish M-Score 13.81 6.30 1.72 6.93 -6.56 -2.95 2.01 0.41 0.76 1.16 29.51 9.37 3.80 68.04 -2.42 -3.95 -3.948
Ohlson O-Score snapshot only -6.250
ROIC (Greenblatt) snapshot only -68.33%
Net-Net WC snapshot only $0.89
EVA snapshot only $-508915320.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BB-
Credit Score 20.00 20.00 61.06 61.83 63.30 63.72 50.10 50.00 54.40 54.80 65.72 65.32 50.23 54.65 43.06 38.54 38.37 38.05 37.58 37.07 37.073
Credit Grade snapshot only 13
Credit Trend snapshot only -1.468
Implied Spread (bps) snapshot only 550.000
Industry Credit Rank snapshot only 29
Sector Credit Rank snapshot only 28

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms